A Phase 3 interventional study of Colchicine and Placebo in Coronary Artery Disease, sponsored by Qingdao Central Hospital. Not yet recruiting at 1 site in China. Open to participants aged 40 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-03-21.
Sponsored by Qingdao Central Hospital · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies testing colchicine in Coronary Artery Disease — 8 open to participants now, 10 under way, 4 of them phase 3. Colchicine · Coronary Artery Disease.
Among the 26 studies testing colchicine in Coronary Artery Disease, this one has the largest planned enrollment, is one of 2 that started in 2022, is one of 6 in phase 3, and was the 9th registered.
4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.
Browse Coronary Artery Disease studies →8 of the 26 studies testing colchicine in Coronary Artery Disease are open now, in 3 countries. Recruiting first, the newest first:
Duke University · Sites in United States
Ages 30–60
Shenyang Northern Hospital · Sites in China
Ages 40–85
AZ Sint-Jan AV · Sites in Belgium
Ages 45+
VA Office of Research and Development · Sites in United States
Ages 18+
Sir Run Run Shaw Hospital · Sites in China
Ages 18+
By country, each count listing its studies:
Colchicine: first FDA approval 1961 (COLBENEMID), first EMA approval 2026. What it is approved for, and how studies give it, is on its page →
Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.
This study: 40 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 6,792 is above the median of 123 across 3,011 interventional studies indexed under Coronary Artery Disease.
Median enrollment 175 across the 26 interventional studies. Of the 13 that completed or were terminated, 4 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 26 has an industry lead sponsor. The 10 most frequent:
Qingdao Central Hospital is the lead sponsor of 25 studies on the registry; 11 are open to participants now.
Qingdao Central Hospital has 1 study filed under Coronary Artery Disease — fewer than ten, so there is no comparison to draw.
3 of the studies testing colchicine in Coronary Artery Disease that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05175274Phase 3Qingdao Central HospitalColchicine Use for Primary Prevention of Coronary Artery Disease | 2027-03-01 |
| NCT06095765Phase 3AZ Sint-Jan AVColchicine in Belgium in Patients With Coronary Artery Disease After Percutaneous Coronary Intervention | 2027-11-01 |
| NCT05850091Massachusetts General HospitalPolygenic Risk-based Detection of Subclinical Coronary Atherosclerosis and Intervention With Statin and Colchicine | 2027-06-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 26 studies testing colchicine in Coronary Artery Disease, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Colchicine has been widely used as an anti-gout medicine in the past decades. Some recent clinical trials have proved that low-dose colchicine can be used as a secondary prevention drug for coronary artery disease because of its anti-inflammatory mechanism. However, the effect on primary prevention has not been observed sufficiently. The objective of this study is to determine whether colchicine reduces the incidence of CAD in patients and its safety for long-term use.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
colchicine 0.5mg every 24 hours for 3 years
Drug: Colchicine
1 placebo tablet every 24 hours for 3 years
Drug: Placebo
Colchicine 0.5mg/tablet
matching placebo
The incidence of CAD
Collect the incidence of CAD during the follow-up time. CAD is defined with the positive stress test, ST depression in ECG with typical symptoms of myocardial ischemia, and progression to myocardial infarction. To further detect patients with occult CAD, the rest of the asymptomatic patients will be subjected to CT coronary angiography, in which CAD is defined with over 50% diameter stenosis in a major coronary artery.
Time frame: 3 years
Occurrence of adverse events in both groups
Collect the occurrence of adverse events in both groups during the drug use.Adverse events include gastrointestinal, liver, hematology, muscle, neurology, other sensory, infectious and death.
Time frame: 3 years
MACE events
To assess the occurence of myocardial infarction, stroke and death from cardiovascular causes during the follow-up time.
Time frame: 3 years
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Dec 2022; primary completion for Mar 2027, 50 months later.
Of 62 phase 3 interventional studies under Coronary Artery Disease, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 58. This study's planned 50 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Colchicine
Qingdao Central Hospital